- Home
- HCM vs GOF Comparison
HCM vs GOF Comparison
Compare HCM & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCM | GOF |
|---|---|---|
| Founded | 2000 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | HCM | GOF |
|---|---|---|
| Price | $13.27 | $8.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $20.59 | N/A |
| AVG Volume (30 Days) | 37.8K | ★ 1.9M |
| Earning Date | 07-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.24 | N/A |
| Revenue Next Year | $11.52 | N/A |
| P/E Ratio | $5.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $8.40 |
| 52 Week High | $16.33 | $13.62 |
Technical Indicators
Market Signals| Indicator | HCM | GOF |
|---|---|---|
| Relative Strength Index (RSI) | 41.46 | 52.33 |
| Support Level | $13.00 | $8.41 |
| Resistance Level | $15.10 | $9.00 |
| Average True Range (ATR) | 0.36 | 0.15 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 3.85 | 67.78 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The Fund's investment objective is to maximize total return through a combination of current income and capital appreciation. It has single operating segment. Its products are Mutual Funds, Wealth Management SMAS, Institutional SMAS, ETFS, UITS, UCITS, CIT, Closed-End Funds, Private Funds, Rydex Funds, and Variable Insurance funds.